Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vincent Medical Holdings Limited ( (HK:1612) ) just unveiled an announcement.
Vincent Medical Holdings reported a strong set of annual results for the year ended 31 December 2025, with revenue rising 16.5% to HK$932.8 million and profit surging 52.8% to HK$108.4 million. Growth was driven primarily by its imaging disposable products segment, where revenue jumped 39.8% to HK$549.7 million and expanded to 58.9% of total sales, reflecting deeper ties and larger business scale with a key customer.
Improved capacity utilisation and operating efficiency lifted the group’s gross margin from 32.5% to 35.1%, while net profit margin increased to 11.6% from 8.9%, underscoring better operating leverage. The company continued investing for future expansion, advancing its new R&D and production facility in Kaiping towards 2026 trial operations, and rewarded shareholders with a higher final dividend, taking total 2025 payouts to HK5.0 cents per share in line with its dividend policy.
The most recent analyst rating on (HK:1612) stock is a Buy with a HK$1.00 price target. To see the full list of analyst forecasts on Vincent Medical Holdings Limited stock, see the HK:1612 Stock Forecast page.
More about Vincent Medical Holdings Limited
Vincent Medical Holdings Limited is a Hong Kong-listed manufacturer of medical devices with a strong focus on imaging disposable products. The group serves healthcare markets through R&D-driven production facilities in mainland China, supplying major customers with single-use imaging consumables and related medical products.
Average Trading Volume: 904,687
Technical Sentiment Signal: Buy
Current Market Cap: HK$586.7M
Learn more about 1612 stock on TipRanks’ Stock Analysis page.